Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06256588




Registration number
NCT06256588
Ethics application status
Date submitted
5/02/2024
Date registered
13/02/2024

Titles & IDs
Public title
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Scientific title
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Secondary ID [1] 0 0
2023-508613-17
Secondary ID [2] 0 0
221530
Universal Trial Number (UTN)
Trial acronym
JADE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neoplasms, Head and Neck 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Head and neck

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dostarlimab
Treatment: Drugs - Placebo

Experimental: Arm A: Dostarlimab -

Placebo comparator: Arm B: Placebo -


Treatment: Drugs: Dostarlimab
Dostarlimab will be administered as an intravenous (IV) infusion

Treatment: Drugs: Placebo
Placebo will be administered as an IV infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)
Timepoint [1] 0 0
Up to approximately 5 years
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to approximately 5 years
Secondary outcome [2] 0 0
Event-free Survival (EFS) assessed by investigator
Timepoint [2] 0 0
Up to approximately 5 years
Secondary outcome [3] 0 0
Number of Participants with treatment emergent adverse events (TEAEs), Immune-mediated TEAEs, and serious adverse events (SAEs) by severity
Timepoint [3] 0 0
Up to approximately 5 years
Secondary outcome [4] 0 0
Number of Participants with TEAEs and SAEs leading to dose delays, withdrawals or death
Timepoint [4] 0 0
Up to approximately 5 years
Secondary outcome [5] 0 0
Number of participants with clinically significant changes in laboratory, vital signs, and safety assessment parameters
Timepoint [5] 0 0
Up to approximately 5 years
Secondary outcome [6] 0 0
Serum Concentration of Dostarlimab
Timepoint [6] 0 0
Up to approximately 15 months
Secondary outcome [7] 0 0
Serum Concentration of Dostarlimab at End of Infusion (C-EoI)
Timepoint [7] 0 0
Up to approximately 15 months
Secondary outcome [8] 0 0
Serum Predose trough concentration (Ctrough) of Dostarlimab
Timepoint [8] 0 0
Up to approximately 15 months
Secondary outcome [9] 0 0
Number of Participants with Anti-Drug Antibodies against Dostarlimab
Timepoint [9] 0 0
Up to approximately 15 months

Eligibility
Key inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply:

* Has newly diagnosed unresected LA histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and completed cisplatin plus radiotherapy (termed "CRT" in this protocol) with curative intent and has no evidence of distant metastatic disease.
* Has provided acceptable core or excisional tissue demonstrating:

* PD-L1 positive tumor status
* If the primary tumor site is oropharyngeal carcinoma, the participant must have p16 IHC testing.
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Has adequate organ function.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Participants are excluded from the study if any of the following criteria apply:

* Has received prior radiation therapy, systemic therapy, targeted therapy, or radical surgery for management of head and neck cancer not considered part of CRT.
* Has cancer outside of the oropharynx, larynx, hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer.
* Has experienced any of the following with prior immunotherapy: any irAE of Grade =3, immune-related severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade [Stevens-Johnson Syndrome, toxic epidermal necrolysis, or DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome], or myocarditis of any grade. Non-clinically significant laboratory abnormalities are not exclusionary.
* Has undergone any major surgical procedure or experienced significant traumatic injury within 28 days prior to enrolment.
* Has any history of interstitial lung disease or pneumonitis (past or current).
* Has cirrhosis or current unstable liver biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
* Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the study results, interfere with their participation for the full duration of the study intervention, or indicate it is not in the best interest of the participant to participate, in the opinion of the investigator.
* Is receiving any other anticancer or experimental therapy. No other experimental therapies (including but not limited to chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, or other experimental drugs) of any kind are permitted while the participant is receiving study intervention.
* Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or coinhibitory T-cell receptor [e.g., Cytotoxic T-lymphocyte associated protein 4 (CTLA4), OX-40, CD137]
* Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 120 days after the last dose of study intervention.
* Has a history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies, fusion proteins, or known allergies to dostarlimab or its excipients.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/03/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
13/07/2029
Actual
Sample size
Target
864
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
GSK Investigational Site - Ballarat
Recruitment hospital [2] 0 0
GSK Investigational Site - Blacktown
Recruitment hospital [3] 0 0
GSK Investigational Site - Douglas
Recruitment hospital [4] 0 0
GSK Investigational Site - Geelong
Recruitment hospital [5] 0 0
GSK Investigational Site - Herston
Recruitment hospital [6] 0 0
GSK Investigational Site - Melbourne
Recruitment postcode(s) [1] 0 0
3350 - Ballarat
Recruitment postcode(s) [2] 0 0
2148 - Blacktown
Recruitment postcode(s) [3] 0 0
4814 - Douglas
Recruitment postcode(s) [4] 0 0
3220 - Geelong
Recruitment postcode(s) [5] 0 0
4029 - Herston
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
Argentina
State/province [21] 0 0
Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Ciudad Autonoma de Buenos Aires
Country [23] 0 0
Argentina
State/province [23] 0 0
Ciudad Autonoma de Buenos Aire
Country [24] 0 0
Argentina
State/province [24] 0 0
Cordoba
Country [25] 0 0
Argentina
State/province [25] 0 0
Rosario
Country [26] 0 0
Argentina
State/province [26] 0 0
San Juan
Country [27] 0 0
Argentina
State/province [27] 0 0
San Miguel de TucumAn
Country [28] 0 0
Argentina
State/province [28] 0 0
Viedma
Country [29] 0 0
Belgium
State/province [29] 0 0
Bruxelles
Country [30] 0 0
Belgium
State/province [30] 0 0
Charleroi
Country [31] 0 0
Belgium
State/province [31] 0 0
Edegem
Country [32] 0 0
Belgium
State/province [32] 0 0
Gent
Country [33] 0 0
Belgium
State/province [33] 0 0
Yvoir
Country [34] 0 0
Brazil
State/province [34] 0 0
Barretos
Country [35] 0 0
Brazil
State/province [35] 0 0
Belo Horizonte
Country [36] 0 0
Brazil
State/province [36] 0 0
Florianopolis
Country [37] 0 0
Brazil
State/province [37] 0 0
Joinville
Country [38] 0 0
Brazil
State/province [38] 0 0
Porto Alegre
Country [39] 0 0
Brazil
State/province [39] 0 0
Salvador
Country [40] 0 0
Brazil
State/province [40] 0 0
Sao Jose Do Rio Preto
Country [41] 0 0
Brazil
State/province [41] 0 0
SAo Paulo
Country [42] 0 0
Brazil
State/province [42] 0 0
VitOria
Country [43] 0 0
Canada
State/province [43] 0 0
Hamilton
Country [44] 0 0
Canada
State/province [44] 0 0
Montreal
Country [45] 0 0
Canada
State/province [45] 0 0
Toronto
Country [46] 0 0
Canada
State/province [46] 0 0
Vancouver
Country [47] 0 0
China
State/province [47] 0 0
Beijing
Country [48] 0 0
China
State/province [48] 0 0
Changsha
Country [49] 0 0
China
State/province [49] 0 0
Changzhou
Country [50] 0 0
China
State/province [50] 0 0
Chengdu
Country [51] 0 0
China
State/province [51] 0 0
Dongguan
Country [52] 0 0
China
State/province [52] 0 0
Fuzhou
Country [53] 0 0
China
State/province [53] 0 0
Guangzhou
Country [54] 0 0
China
State/province [54] 0 0
Hangzhou
Country [55] 0 0
China
State/province [55] 0 0
Hefei
Country [56] 0 0
China
State/province [56] 0 0
Hengyang
Country [57] 0 0
China
State/province [57] 0 0
Jinan
Country [58] 0 0
China
State/province [58] 0 0
Lanzhou
Country [59] 0 0
China
State/province [59] 0 0
Linyi
Country [60] 0 0
China
State/province [60] 0 0
Nanchang
Country [61] 0 0
China
State/province [61] 0 0
Nanning
Country [62] 0 0
China
State/province [62] 0 0
Shanghai
Country [63] 0 0
China
State/province [63] 0 0
Shenyang
Country [64] 0 0
China
State/province [64] 0 0
Taiyuan
Country [65] 0 0
China
State/province [65] 0 0
Wuhan
Country [66] 0 0
China
State/province [66] 0 0
Xiamen
Country [67] 0 0
China
State/province [67] 0 0
Zhengzhou
Country [68] 0 0
China
State/province [68] 0 0
Zhuhai
Country [69] 0 0
Czechia
State/province [69] 0 0
Olomouc
Country [70] 0 0
Czechia
State/province [70] 0 0
Prague
Country [71] 0 0
Czechia
State/province [71] 0 0
Praha 8
Country [72] 0 0
Czechia
State/province [72] 0 0
Praha
Country [73] 0 0
Czechia
State/province [73] 0 0
Zlin
Country [74] 0 0
France
State/province [74] 0 0
Caen Cedex 5
Country [75] 0 0
France
State/province [75] 0 0
Dijon Cedex
Country [76] 0 0
France
State/province [76] 0 0
Marseille cedex 5
Country [77] 0 0
France
State/province [77] 0 0
Poitiers
Country [78] 0 0
France
State/province [78] 0 0
Rennes Cedex
Country [79] 0 0
France
State/province [79] 0 0
Rouen Cedex 1
Country [80] 0 0
France
State/province [80] 0 0
Valenciennes cedex
Country [81] 0 0
France
State/province [81] 0 0
Vanduvre-lEs-Nancy Cedex
Country [82] 0 0
Germany
State/province [82] 0 0
Augsburg
Country [83] 0 0
Germany
State/province [83] 0 0
Berlin
Country [84] 0 0
Germany
State/province [84] 0 0
Erlangen
Country [85] 0 0
Germany
State/province [85] 0 0
Essen
Country [86] 0 0
Germany
State/province [86] 0 0
Hamburg
Country [87] 0 0
Germany
State/province [87] 0 0
Hannover
Country [88] 0 0
Germany
State/province [88] 0 0
Straubing
Country [89] 0 0
Greece
State/province [89] 0 0
Athens
Country [90] 0 0
Greece
State/province [90] 0 0
Larissa
Country [91] 0 0
Greece
State/province [91] 0 0
Thessaloniki
Country [92] 0 0
Hungary
State/province [92] 0 0
Gyor
Country [93] 0 0
Hungary
State/province [93] 0 0
Kaposvar
Country [94] 0 0
Hungary
State/province [94] 0 0
Nyiregyhaza
Country [95] 0 0
Hungary
State/province [95] 0 0
SalgOtarjAn
Country [96] 0 0
India
State/province [96] 0 0
Bengaluru
Country [97] 0 0
India
State/province [97] 0 0
Bhubaneswar
Country [98] 0 0
India
State/province [98] 0 0
Hyderabad
Country [99] 0 0
India
State/province [99] 0 0
Kolkata
Country [100] 0 0
India
State/province [100] 0 0
Mumbai
Country [101] 0 0
India
State/province [101] 0 0
Nashik
Country [102] 0 0
India
State/province [102] 0 0
Nehru Nagar Belagavi Karnataka 590010
Country [103] 0 0
India
State/province [103] 0 0
Surat
Country [104] 0 0
India
State/province [104] 0 0
Trivandrum
Country [105] 0 0
India
State/province [105] 0 0
Vijayawada
Country [106] 0 0
Israel
State/province [106] 0 0
Haifa
Country [107] 0 0
Israel
State/province [107] 0 0
Jerusalem
Country [108] 0 0
Israel
State/province [108] 0 0
Tel Aviv
Country [109] 0 0
Italy
State/province [109] 0 0
Milano
Country [110] 0 0
Italy
State/province [110] 0 0
Napoli
Country [111] 0 0
Italy
State/province [111] 0 0
Padova
Country [112] 0 0
Italy
State/province [112] 0 0
Pavia
Country [113] 0 0
Italy
State/province [113] 0 0
Prato
Country [114] 0 0
Italy
State/province [114] 0 0
Roma
Country [115] 0 0
Italy
State/province [115] 0 0
Rozzano MI
Country [116] 0 0
Italy
State/province [116] 0 0
Savona
Country [117] 0 0
Japan
State/province [117] 0 0
Aichi
Country [118] 0 0
Japan
State/province [118] 0 0
Chiba
Country [119] 0 0
Japan
State/province [119] 0 0
Ehime
Country [120] 0 0
Japan
State/province [120] 0 0
Fukuoka
Country [121] 0 0
Japan
State/province [121] 0 0
Hokkaido
Country [122] 0 0
Japan
State/province [122] 0 0
Hyogo
Country [123] 0 0
Japan
State/province [123] 0 0
Iwate
Country [124] 0 0
Japan
State/province [124] 0 0
Kanagawa
Country [125] 0 0
Japan
State/province [125] 0 0
Kyoto
Country [126] 0 0
Japan
State/province [126] 0 0
Miyagi
Country [127] 0 0
Japan
State/province [127] 0 0
Niigata
Country [128] 0 0
Japan
State/province [128] 0 0
Osaka
Country [129] 0 0
Japan
State/province [129] 0 0
Saitama
Country [130] 0 0
Japan
State/province [130] 0 0
Shizuoka
Country [131] 0 0
Japan
State/province [131] 0 0
Tokyo
Country [132] 0 0
Japan
State/province [132] 0 0
Tottori
Country [133] 0 0
Korea, Republic of
State/province [133] 0 0
Busan
Country [134] 0 0
Korea, Republic of
State/province [134] 0 0
Pusan
Country [135] 0 0
Korea, Republic of
State/province [135] 0 0
Seoul
Country [136] 0 0
Korea, Republic of
State/province [136] 0 0
Suwon Gyeonggi-do
Country [137] 0 0
Mexico
State/province [137] 0 0
Ciudad de Mexico
Country [138] 0 0
Mexico
State/province [138] 0 0
Guadalajara
Country [139] 0 0
Mexico
State/province [139] 0 0
Oaxaca
Country [140] 0 0
Norway
State/province [140] 0 0
Bergen
Country [141] 0 0
Norway
State/province [141] 0 0
Oslo
Country [142] 0 0
Norway
State/province [142] 0 0
Troms
Country [143] 0 0
Poland
State/province [143] 0 0
Bielsko-Biala
Country [144] 0 0
Poland
State/province [144] 0 0
Gliwice
Country [145] 0 0
Poland
State/province [145] 0 0
Katowice
Country [146] 0 0
Poland
State/province [146] 0 0
Koszalin
Country [147] 0 0
Poland
State/province [147] 0 0
Olsztyn
Country [148] 0 0
Poland
State/province [148] 0 0
Przemysl
Country [149] 0 0
Poland
State/province [149] 0 0
Siedlce
Country [150] 0 0
Poland
State/province [150] 0 0
Warszawa
Country [151] 0 0
Portugal
State/province [151] 0 0
Coimbra
Country [152] 0 0
Portugal
State/province [152] 0 0
Faro
Country [153] 0 0
Portugal
State/province [153] 0 0
Lisboa
Country [154] 0 0
Portugal
State/province [154] 0 0
Matosinhos
Country [155] 0 0
Portugal
State/province [155] 0 0
Porto
Country [156] 0 0
Portugal
State/province [156] 0 0
Vila Nova de Gaia
Country [157] 0 0
Romania
State/province [157] 0 0
Bucharest
Country [158] 0 0
Romania
State/province [158] 0 0
Bucuresti
Country [159] 0 0
Romania
State/province [159] 0 0
Craiova
Country [160] 0 0
Romania
State/province [160] 0 0
Iasi
Country [161] 0 0
Romania
State/province [161] 0 0
Oradea
Country [162] 0 0
Romania
State/province [162] 0 0
Pitesti
Country [163] 0 0
Romania
State/province [163] 0 0
Suceava
Country [164] 0 0
Romania
State/province [164] 0 0
Timisoara
Country [165] 0 0
Spain
State/province [165] 0 0
BaracaldoVizcaya
Country [166] 0 0
Spain
State/province [166] 0 0
Barcelona
Country [167] 0 0
Spain
State/province [167] 0 0
Cartagena Murcia
Country [168] 0 0
Spain
State/province [168] 0 0
HebrOn
Country [169] 0 0
Spain
State/province [169] 0 0
Jerez
Country [170] 0 0
Spain
State/province [170] 0 0
L'Hospitalet De Llobrega
Country [171] 0 0
Spain
State/province [171] 0 0
Lugo
Country [172] 0 0
Spain
State/province [172] 0 0
Madrid
Country [173] 0 0
Spain
State/province [173] 0 0
Pamplona
Country [174] 0 0
Spain
State/province [174] 0 0
Salamanca
Country [175] 0 0
Spain
State/province [175] 0 0
Santander
Country [176] 0 0
Spain
State/province [176] 0 0
Zaragoza
Country [177] 0 0
Sweden
State/province [177] 0 0
Goteborg
Country [178] 0 0
Sweden
State/province [178] 0 0
Stockholm
Country [179] 0 0
Sweden
State/province [179] 0 0
Uppsala
Country [180] 0 0
Taiwan
State/province [180] 0 0
Changhua
Country [181] 0 0
Taiwan
State/province [181] 0 0
Kaohsiung
Country [182] 0 0
Taiwan
State/province [182] 0 0
Taichung
Country [183] 0 0
Taiwan
State/province [183] 0 0
Taipei
Country [184] 0 0
Turkey
State/province [184] 0 0
Ankara
Country [185] 0 0
Turkey
State/province [185] 0 0
Antalya
Country [186] 0 0
Turkey
State/province [186] 0 0
Istanbul
Country [187] 0 0
United Kingdom
State/province [187] 0 0
Edinburgh
Country [188] 0 0
United Kingdom
State/province [188] 0 0
Gloucester
Country [189] 0 0
United Kingdom
State/province [189] 0 0
London
Country [190] 0 0
United Kingdom
State/province [190] 0 0
Nottingham
Country [191] 0 0
United Kingdom
State/province [191] 0 0
Sutton
Country [192] 0 0
United Kingdom
State/province [192] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
US GSK Clinical Trials Call Center
Address 0 0
Country 0 0
Phone 0 0
877-379-3718
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
When will data be available (start and end dates)?
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Available to whom?
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://www.gsk.com/en-gb/innovation/trials/data-transparency/


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06256588